Literature DB >> 34992970

CSF and Circulating NfL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes: Meta-analysis.

Efthalia Angelopoulou1, Anastasia Bougea1, Andreas Papadopoulos1, Nikolaos Papagiannakis1, Athina-Maria Simitsi1, Christos Koros1, Marios K Georgakis1, Leonidas Stefanis1.   

Abstract

PURPOSE OF REVIEW: To evaluate whether CSF and circulating neurofilament light chain (NfL), a marker of axonal damage, could discriminate Parkinson disease (PD) from atypical parkinsonian syndromes (APSs). RECENT
FINDINGS: MEDLINE and Scopus were systematically searched, and 15 studies were included (1,035 patients with PD and 930 patients with APS). CSF NfL levels were 1.26 SDs higher in the APS group compared to the PD group (g = 1.26 [95% confidence interval 0.99-1.53]), and circulating NfL levels were 1.53 SDs higher in the APS group compared to the PD group (g = 1.53 [95% confidence interval 1.15-1.91]); 4 studies, 307 patients with PD, 197 patients with APS. Pooled areas under the curve were 0.941 (0.916-0.965) and 0.874 (0.802-0.946) for CSF and circulating NfL, corresponding to average sensitivities of 86% (79%-90%) and 91% (86%-95%), and specificity of 88% (82%-92%) and 76% (62%-85%), respectively.
SUMMARY: These results strongly support the high diagnostic accuracy of both CSF and circulating NfL in differentiating PD from APS, highlighting their usefulness as promising biomarkers.
© 2021 American Academy of Neurology.

Entities:  

Year:  2021        PMID: 34992970      PMCID: PMC8723936          DOI: 10.1212/CPJ.0000000000001116

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  39 in total

1.  Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders.

Authors:  Irene Litvan; Kailash P Bhatia; David J Burn; Christopher G Goetz; Anthony E Lang; Ian McKeith; Niall Quinn; Kapil D Sethi; Cliff Shults; Gregor K Wenning
Journal:  Mov Disord       Date:  2003-05       Impact factor: 10.338

2.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

3.  CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.

Authors:  B Holmberg; B Johnels; P Ingvarsson; B Eriksson; L Rosengren
Journal:  Parkinsonism Relat Disord       Date:  2001-09       Impact factor: 4.891

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 5.  Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia.

Authors:  Stephen N Gomperts
Journal:  Continuum (Minneap Minn)       Date:  2016-04

6.  Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Authors:  Claire Bridel; Wessel N van Wieringen; Henrik Zetterberg; Betty M Tijms; Charlotte E Teunissen; José C Alvarez-Cermeño; Ulf Andreasson; Markus Axelsson; David C Bäckström; Ales Bartos; Maria Bjerke; Kaj Blennow; Adam Boxer; Lou Brundin; Joachim Burman; Tove Christensen; Lenká Fialová; Lars Forsgren; Jette L Frederiksen; Magnus Gisslén; Elizabeth Gray; Martin Gunnarsson; Sara Hall; Oskar Hansson; Megan K Herbert; Joel Jakobsson; Jan Jessen-Krut; Shorena Janelidze; Gudmundur Johannsson; Michael Jonsson; Ludwig Kappos; Mohsen Khademi; Michael Khalil; Jens Kuhle; Mikael Landén; Ville Leinonen; Giancarlo Logroscino; Ching-Hua Lu; Jan Lycke; Nadia K Magdalinou; Andrea Malaspina; Niklas Mattsson; Lieke H Meeter; Sanjay R Mehta; Signe Modvig; Tomas Olsson; Ross W Paterson; Josué Pérez-Santiago; Fredrik Piehl; Yolande A L Pijnenburg; Okko T Pyykkö; Oskar Ragnarsson; Julio C Rojas; Jeppe Romme Christensen; Linda Sandberg; Carole S Scherling; Jonathan M Schott; Finn T Sellebjerg; Isabella L Simone; Tobias Skillbäck; Morten Stilund; Peter Sundström; Anders Svenningsson; Rosanna Tortelli; Carla Tortorella; Alessandro Trentini; Maria Troiano; Martin R Turner; John C van Swieten; Mattias Vågberg; Marcel M Verbeek; Luisa M Villar; Pieter Jelle Visser; Anders Wallin; Andreas Weiss; Carsten Wikkelsø; Edward J Wild
Journal:  JAMA Neurol       Date:  2019-09-01       Impact factor: 18.302

Review 7.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

8.  Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers.

Authors:  Stephanie Mangesius; Sara Mariotto; Sergio Ferrari; Sergiy Pereverzyev; Hannes Lerchner; Lukas Haider; Elke R Gizewski; Gregor Wenning; Klaus Seppi; Markus Reindl; Werner Poewe
Journal:  Parkinsonism Relat Disord       Date:  2020-06-22       Impact factor: 4.402

9.  CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.

Authors:  Megan K Herbert; Marjolein B Aerts; Marijke Beenes; Niklas Norgren; Rianne A J Esselink; Bastiaan R Bloem; H Bea Kuiperij; Marcel M Verbeek
Journal:  Front Neurol       Date:  2015-05-05       Impact factor: 4.003

10.  Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.

Authors:  Sara Hall; Shorena Janelidze; Yulia Surova; Håkan Widner; Henrik Zetterberg; Oskar Hansson
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.